About SK bioscience
SK bioscience is a company based in Seongnam-si (South Korea) founded in 2018. The company has 1,020 employees as of December 31, 2024. SK bioscience has completed 1 acquisition, including IDT Biologika. SK bioscience operates in a competitive market with competitors including AmerisourceBergen, Pfizer, CHEPLAPHARM, Entero Healthcare and EBOS Group, among others.
- Headquarter Seongnam-si, South Korea
- Employees 1020 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sk Bioscience Co.,Ltd.
-
Annual Revenue
$181.4 M (USD)-27.59as on Dec 31, 2024
-
Net Profit
-$36.53 M (USD)-341.43as on Dec 31, 2024
-
EBITDA
-$80.66 M (USD)-1258.01as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
1020
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of SK bioscience
SK bioscience is a publicly listed company on the KRX with ticker symbol 302440 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of SK bioscience
Detailed funding history for SK bioscience
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SK bioscience
SK bioscience has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include IDT Biologika.
Investment portfolio details for SK bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Vaccines and biologics are developed and manufactured by IDT Biologika.
|
Locked | Locked | 1921 | Locked |
Complete acquisition details for SK bioscience
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - SK bioscience
Detailed financials for SK bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sk Bioscience Comparisons
Peer comparison for SK bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SK bioscience
SK bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as AmerisourceBergen, Pfizer, CHEPLAPHARM, Entero Healthcare and EBOS Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical distribution and supply chain services are provided globally.
|
|
| Locked | Locked | Locked |
Pharmaceutical products for treating multiple diseases are provided.
|
|
| Locked | Locked | Locked |
Branded pharmaceutical products are developed, marketed, and distributed globally.
|
|
| Locked | Locked | Locked |
India's leading healthcare products distribution platform
|
|
| Locked | Locked | Locked |
Wholesaler & distributor of healthcare, medical, and pharmaceutical products
|
|
| Locked | Locked | Locked |
Diversified drugs are distributed by Renee in the United States.
|
Detailed competitors of SK bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sk Bioscience
Complete news archive for SK bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SK bioscience
SK bioscience was founded in 2018.
SK bioscience is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
As of Dec 31, 2024, the latest employee count at SK bioscience is 1,020.
Annual revenue of SK bioscience is $181.4M as on Dec 31, 2024.
SK bioscience was founded in 2018 and is headquartered in Seongnam-si, South Korea. Operations center on the vaccine sector, where routine vaccines and COVID-19 candidates are developed and manufactured. Expertise in research, development, and production processes is applied to support these activities. The companys domain, skbioscience.com, facilitates information on its vaccine portfolio and advancements.
SK bioscience's top competitors include Pfizer, Entero Healthcare and AmerisourceBergen.
Yes, SK bioscience is publicly traded on KRX under the ticker symbol 302440.
SK bioscience has made 1 acquisition, including IDT Biologika.
The ticker symbol of SK bioscience is 302440 on KRX.